Clinical Trial

Effects of Resistance Training Intensity on Cardiovascular Parameters of Hypertensive Women

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 5, 2024 (before its estimated September 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to understand about the effects of resistance training (RT) intensity on cardiovascular parameters in postmenopausal women with systemic arterial hypertension (SAH). The main research questions are: * Does the intensity of RT impact blood pressure (BP) in postmenopausal women with SAH? * How does RT intensity affect heart rate (HR) and their variability (HRV), endothelial function (EF), and nitric oxide (NO) biomarker synthesis in this population? * What are the effects of RT intensity on affectivity and rate of perceived exertion (RPE)? Researchers will compare two different intensities of RT (60% of the load for 1 repetition maximum \[1RM\] and 80% of 1RM) to determine their effects on the mentioned cardiovascular and perceptual parameters. Participants will: In the acute experiment: * Perform the same RT session in a crossover design, training with 60% of 1RM in one condition and 80% of 1RM in another condition * Have BP, HR, and HRV measured before, immediately after, and for one hour post-session * Report affectivity before each session and at the end, along with RPE In the chronic experiment: * Be randomized into two groups: one training with 60% of 1RM and the other with 80% of 1RM * Undergo a 10-week intervention period with evaluations before, during, and after the intervention * Have BP, HR, affective responses, and RPE measured at multiple time points * Have EF, HRV, and salivary concentrations of NO biomarkers assessed before and after the intervention
Trial Details
NCT Number NCT06538454
Lead Sponsor University of Sao Paulo
Conditions Arterial Hypertension, Postmenopausal; Menorrhagia, Cardiovascular Diseases
Enrollment 24 participants
Start Date 2024-07-23
Primary Completion 2024-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2024-08-05